HAE on NYSE

Haemonetics

Logo: MelanieCommunications, Public domain, via Wikimedia Commons5

Healthcare company

Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s. Today, the company has expanded and has offices located in 16 countries.3 It employed 3,300 people.1 Wikipedia text CC BY-SA 4.0

Price unavailable

Last updated Oct 21, 2026.

Overview

$1.3BRevenue, fiscal 20266
$97.3MNet income, fiscal 20266
1971Founded1

Compare with Penumbra, NuVasive or MERIT MEDICAL SYSTEMS INC, or pick any stock.

  • TickerHAE on NYSE1
  • Industrybiomedical engineering1
  • HeadquartersBoston1
  • Websitewww.haemonetics.com
  • Incorporated inMA7
  • Business address125 Summer Street, Boston, Ma 021107
  • Filer categoryLarge accelerated filer7
  • Legal formDomestic Business Corporation4
  • LEI549300ZEL6TXZS6F5F954
  • StatusActive4
  • LEI statusIssued and current4
  • Registered addressC/O C T CORPORATION SYSTEM, 02110 Boston, United States4
  • Registered withCorporations Division (Secretary of the Commonwealth's Office), 0428822734

Haemonetics Corporation is a global provider of blood and plasma supplies and services. The company was founded in Natick, Massachusetts by Dr. Allen (Jack) Latham in the 1970s.3

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2026

59.0%Gross margin6
11.7%Operating margin6
7.3%Net margin6
-2.0%Revenue growth, 20266
12.2%Return on equity6
1.53×Debt to equity6
$260.4MFree cash flow6

What sells

Revenue by product, business segment and region, as the company reports it to the SEC.

Products and services

Hospital Products and Services brought in 73% of the revenue Haemonetics broke down this way in fiscal 2026.

  1. Hospital Products and Services$588.3M673%up 4% from 2025
  2. Blood Center Products and Services$221.3M627%down 15% from 2025
Products and services by year
Products and services202420252026
Hospital Products and Services$456.3M$564.3M$588.3M
Blood Center Products and Services$283.2M$261.1M$221.3M

Business segments

Hospital brought in 44% of the revenue Haemonetics broke down this way in fiscal 2026.

  1. Hospital$588.3M644%up 4% from 2025
  2. Plasma$524.5M639%down 2% from 2025
  3. Blood Center$221.3M617%down 15% from 2025
Business segments by year
Business segments202420252026
Hospital$456.3M$564.3M$588.3M
Plasma$569.5M$535.4M$524.5M
Blood Center$283.2M$261.1M$221.3M

Regions

United States brought in 74% of the revenue Haemonetics broke down this way in fiscal 2026.

  1. United States$982.2M674%down 3% from 2025
  2. Europe$185.0M614%up 5% from 2025
  3. Asia$87.2M67%down 6% from 2025
  4. Japan$68.2M65%up 9% from 2025
  5. Other Country or Region$11.4M61%down 42% from 2025
Regions by year
Regions202420252026
United States$970.0M$1.0B$982.2M
Europe$160.1M$175.7M$185.0M
Asia$107.5M$92.3M$87.2M
Japan$58.1M$62.4M$68.2M
Other Country or Region$13.3M$19.5M$11.4M

Where the money goes

Where each dollar of revenue went, fiscal 2026

  • Cost of revenue41¢$546.4M
  • Research and development4¢$59.8M
  • Selling, general and admin33¢$442.4M
  • Other costs12¢$157.4M
  • Income tax2¢$30.7M
  • Profit7¢$97.3M

Out of $1.3B in revenue.6

Where each dollar of operating cash went, fiscal 2026

  • Capital spending11¢$32.8M
  • Share buybacks60¢$175.0M
  • Kept or used elsewhere29¢$85.4M

Out of $293.2M of cash from operations.6

Financial statements

Revenue10111213146$1.3B in 2026+38% since 2019
0$500.0M$1.0B$1.5B2019: $967.6M$967.6M20192020: $988.5M$988.5M2020+2%2021: $870.5M$870.5M2021−12%2022: $993.2M$993.2M2022+14%2023: $1.2B$1.2B2023+18%2024: $1.3B$1.3B2024+12%2025: $1.4B$1.4B2025+4%2026: $1.3B$1.3B2026−2%
Gross profit10111213146$787.6M in 2026+89% since 2019
0$200.0M$400.0M$600.0M$800.0M2019: $417.5M$417.5M20192020: $484.5M$484.5M2020+16%2021: $397.8M$397.8M2021−18%2022: $505.5M$505.5M2022+27%2023: $615.1M$615.1M2023+22%2024: $691.5M$691.5M2024+12%2025: $749.0M$749.0M2025+8%2026: $787.6M$787.6M2026+5%
Operating income10111213146$156.7M in 2026+88% since 2019
0$100.0M$200.0M$300.0M2019: $83.5M$83.5M20192020: $103.4M$103.4M2020+24%2021: $89.7M$89.7M2021−13%2022: $80.8M$80.8M2022−10%2023: $156.0M$156.0M2023+93%2024: $164.9M$164.9M2024+6%2025: $221.8M$221.8M2025+35%2026: $156.7M$156.7M2026−29%
Net income10111213146$97.3M in 2026+77% since 2019
0$50.0M$100.0M$150.0M$200.0M2019: $55.0M$55.0M20192020: $76.5M$76.5M2020+39%2021: $79.5M$79.5M2021+4%2022: $43.4M$43.4M2022−45%2023: $115.4M$115.4M2023+166%2024: $117.6M$117.6M2024+2%2025: $167.7M$167.7M2025+43%2026: $97.3M$97.3M2026−42%

Every line of the income statement as filed: the last 3 fiscal years, latest first.6

Period ending2026-03-312025-03-312024-03-31
Net revenues$1.3B$1.4B$1.3B
Cost of goods sold$546.4M$611.9M$617.5M
Gross profit$787.6M$749.0M$691.5M
Research and development$59.8M$62.7M$54.4M
Selling, general and administrative$442.4M$436.8M$429.8M
Amortization of acquired intangible assets$44.0M$48.3M$32.0M
Remeasurement of contingent consideration-$1.9M-$23.0M$0
Impairment of intangible assets$86.5M$2.4M$10.4M
Total operating expenses$630.9M$527.1M$526.7M
Operating income$156.7M$221.8M$164.9M
Interest and other expense, net-$28.7M-$9.7M-$13.0M
Income before provision for income taxes$128.0M$212.1M$151.9M
Provision for income taxes$30.7M$44.4M$34.3M
Net income$97.3M$167.7M$117.6M
Basic (in dollars per share)$2.06$3.33$2.32
Diluted (in dollars per share)$2.05$3.31$2.29
Basic (in shares)47.2M shares50.3M shares50.7M shares
Diluted (in shares)47.4M shares50.7M shares51.4M shares

Compare Haemonetics with another company

Corporate structure

Haemonetics sits at the top of its group. 32 entities, 19 countries on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Haemonetics

  • Haemonetics Boston, Massachusetts, United States
    • 5D Information Management, Inc. Subsidiary · Delaware, United States
    • Advanced Cooling Therapy, LLC Subsidiary · Delaware, United States
    • Arryx, Inc. Subsidiary · Nevada, United States
    • Cardiva Medical, Inc. Subsidiary · Delaware, United States
    • Enicor GmbH Subsidiary · Germany
    • Global Med Technologies, Inc. Subsidiary · Colorado, United States
    • Haemonetics (Hong Kong) Limited Subsidiary · Hong Kong
    • Haemonetics (Shanghai) Management Co. Ltd. Subsidiary · China
    • Haemonetics Asia Incorporated Subsidiary · Delaware, United States
    • Haemonetics Asia UK Ltd. Subsidiary · United Kingdom
    • Haemonetics Canada Ltd. Subsidiary · British Columbia, Canada
    • Haemonetics CZ, spol. s.r.o. Subsidiary · Czechia
    • Haemonetics France S.a.r.l Subsidiary · France
    • Haemonetics Handelsgesellschaft m.b.H. Subsidiary · Austria
    • Haemonetics Healthcare India Private Limited Subsidiary · India
    • Haemonetics Interventional Technologies Limited Subsidiary · Ireland
    • Haemonetics Italia s.r.l. Subsidiary · Italy
    • Haemonetics Japan GK Subsidiary · Japan
    • Haemonetics Malaysia Sdn. Bhd. Subsidiary · Malaysia
    • HAEMONETICS MANUFACTURING, INC. Subsidiary · Wilmington, Delaware, United States
    • Haemonetics Mexico Manufacturing, S.de R.L. de C.V. Subsidiary · Mexico
    • Haemonetics New Zealand Limited Subsidiary · New Zealand
    • HAEMONETICS S.A. Subsidiary · Nyon, Switzerland
    • Haemonetics Singapore Pte. Ltd. Subsidiary · Singapore
    • Haemoscope Corporation Subsidiary · Massachusetts, United States
    • and 6 more

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); subsidiaries listed in Exhibit 21 of annual reports filed with the SEC; major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Haemonetics reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$841.8M6 Mar 28, 2026$837.2M6 Mar 29, 2025+0.6%
Accumulated depreciation$536.1M6 Mar 28, 2026$553.1M6 Mar 29, 2025−3.1%
Property and equipment, net$305.8M6 Mar 28, 2026$284.1M6 Mar 29, 2025+7.6%
Operating-lease assets (leased space)$39.6M6 Mar 28, 2026$47.5M6 Mar 29, 2025−16.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$245.4M6 Mar 28, 2026$306.8M6 Mar 29, 2025−20.0%

Intangibles and goodwill

ItemLatestA year beforeChange
Goodwill$656.4M6 Mar 28, 2026$604.3M6 Mar 29, 2025+8.6%
Intangible assets, net (excluding goodwill)$447.7M6 Mar 28, 2026$455.7M6 Mar 29, 2025−1.8%
Indefinite-lived intangibles (excluding goodwill)$5.9M6 Mar 28, 2026$9.2M6 Mar 29, 2025−35.8%
Finite-lived intangibles, gross$805.5M6 Mar 28, 2026$762.9M6 Mar 29, 2025+5.6%
Accumulated amortization$363.8M6 Mar 28, 2026$316.3M6 Mar 29, 2025+15.0%
Finite-lived intangibles, net$441.8M6 Mar 28, 2026$446.6M6 Mar 29, 2025−1.1%

Inventory

ItemLatestA year beforeChange
Inventory, total$306.4M6 Mar 28, 2026$365.1M6 Mar 29, 2025−16.1%
Raw materials$114.9M6 Mar 28, 2026$128.6M6 Mar 29, 2025−10.7%
Work in process$12.0M6 Mar 28, 2026$15.0M6 Mar 29, 2025−19.9%
Finished goods$179.5M6 Mar 28, 2026$221.6M6 Mar 29, 2025−19.0%

Properties, in its own words

As of March 28, 2026, our global headquarters are located in Boston, Massachusetts and our principal manufacturing centers are located in Pennsylvania within the U.S., as well as internationally in Malaysia, Mexico, Canada and Ireland. Our products are distributed worldwide from our primary distribution centers in Utah and Pennsylvania, as well as smaller locations globally. We believe all of these facilities are well-maintained and suitable for the operations conducted in them. Our U.S., Malaysia and Mexico facilities manufacture products for more than one of our business segments.

The following is a summary of our facilities as of March 28, 2026 (in approximate square feet):

The rest of Item 2

Owned · Leased · Total

U.S. · — · 429,689 · 429,689

International · 378,000 · 316,413 · 694,413

Total · 378,000 · 746,102 · 1,124,102

Item 2 of the 10-K filed May 20, 2026.19

The story

The company was founded in 1971. Haemonetics started out producing the containers and bags required for blood collection. The Latham Bowl was a disposable container that could automate the separation of blood by centrifugation. Through the 90's, the company added additional product lines and technologies. The company opened a manufacturing facility in Holbrook, Massachusetts in 1988.

In 1995 the company purchased the Intravenous Solutions manufacturing facility in Union, South Carolina.

Additional acquisitions grew the company and expanded its services. In the following years the company branched off to making the whole plasma collection station including the machine, supplies and software for plasma collection. These acquisitions included Edmonton-based Fifth Dimension (5D) Information Systems to gain entry into the blood and plasma software industry. Further acquisitions include Chicago-based Arryx in July 2006, Information Data Management, Inc. in January 2007, the acquisition of a division of Haemoscope in 2007, the acquisition of Infonale in July 2007, and, in 2009, Chico, California-based Altivation and Tucson, Arizona-based Sebra.

On August 21, 2007, 5D and IDM were officially merged into a new subsidiary called Haemonetics Software Solutions. The employees at both Edmonton (5D) and Rosemont (IDM) continue to work from their respective offices.

Further acquisitions included the April 2009 acquisition of Neoteric Technology Ltd and the April 2010 acquisition of California-based Global Med Technologies, Inc. Haemonetics acquired the Pall Corporation's transfusion medicine business on August 1, 2012 for ~$550 million.

In April 2024, it was announced Haemonetics had completed its acquisition of the Chicago-headquartered medical device temperature regulation manufacturer, Attune Medical for $160 million.

From Wikipedia’s article on Haemonetics, shared under CC BY-SA 4.0.8

Leadership

Who has led Haemonetics, and when. Pick a name to see everywhere that person has worked.

Board members and other officers (46)

Products and brands

Haemonetics products can be considered as belonging to two broad categories. Donor products (marketed to the blood donation industry, these include products that automate the blood donation process, automate the processing of blood, support pathogen inactivation and bacterial detection of blood, and test blood hematocrit); and products that are marketed to the surgical suite for blood loss management for patients. These products include surgical blood salvage (or "autotransfusion") devices, surgical field blood suction systems, and blood and patient warming systems.

Hemostasis

TEG 5000

Kaolin TEG

Kaolin TEG with Heparinase

Read the full text

RapidTEG

TEG Functional Fibrinogen

TEG PlateletMapping

TEG 6S

From Wikipedia’s article on Haemonetics, shared under CC BY-SA 4.0.8

Subsidiaries and ownership

Subsidiaries (Exhibit 21)

  • 5D Information Management, Inc. Delaware9
  • Advanced Cooling Therapy, LLC Delaware9
  • Arryx, Inc. Nevada9
  • Cardiva Medical, Inc. Delaware9
  • Enicor GmbH Germany9
  • Global Med Technologies, Inc. Colorado9
  • Haemonetics (Hong Kong) Limited Hong Kong9
  • Haemonetics (Shanghai) Management Co. Ltd. Shanghai,China9
  • Haemonetics Asia Incorporated Delaware9
  • Haemonetics Asia UK Ltd. United Kingdom9
  • Haemonetics CZ, spol. s.r.o. Czech Republic9
  • Haemonetics Canada Ltd. British Columbia9
  • Haemonetics France S.a.r.l France9
  • Haemonetics GmbH Germany9
  • Haemonetics Handelsgesellschaft m.b.H. Austria9
  • Haemonetics Healthcare India Private Limited India9
  • Haemonetics Interventional Technologies Limited Ireland9
  • Haemonetics Italia s.r.l. Italy9
  • Haemonetics Japan GK Japan9
  • Haemonetics Limited United Kingdom9
  • Haemonetics Malaysia Sdn. Bhd. Malaysia9
  • Haemonetics Manufacturing, Inc. Delaware9
  • Haemonetics Mexico Manufacturing, S.de R.L. de C.V. Mexico9
  • Haemonetics New Zealand Limited New Zealand9
All 34 listed subsidiaries
  • Haemonetics S.A. Switzerland9
  • Haemonetics Singapore Pte. Ltd. Singapore9
  • Haemoscope Corporation Massachusetts9
  • OpSens B.V. Netherlands9
  • OpSens Inc. Quebec9
  • OpSens Medical, Inc. Delaware9
  • OpSens Solutions Inc. Alberta9
  • Vivasure Medical Limited Ireland9
  • Vivasure Medical UK Ltd. United Kingdom9
  • Vivasure Medical US, Inc. Delaware9

The subsidiaries the company lists in Exhibit 21 of its annual report, as filed.

Timeline

  1. Oct 8, 20268-K Regulation FD disclosure85
  2. Aug 18, 20268-K Regulation FD disclosure86
  3. Aug 6, 20268-K Results of operations87
  4. Jul 28, 20268-K Executive or director change; Shareholder vote88
  5. Jun 5, 20268-K Regulation FD disclosure89
  6. May 7, 20268-K Results of operations90
  7. May 1, 20268-K Executive or director change91
  8. Mar 3, 20268-K Regulation FD disclosure92
  9. Feb 12, 20268-K Regulation FD disclosure93
  10. Feb 5, 20268-K Results of operations94
  11. Jan 9, 20268-K Other events95
  12. Nov 6, 20258-K Results of operations96
  13. May 18, 2016New chief executive Christopher Simon becomes CEO20
  14. Apr 6, 2009New chief executive Brian Concannon becomes CEO21
  15. May 20, 2008New chief executive Brad Nutter becomes CEO22
  16. Jan 3, 1994Went public Listed on NYSE1
  17. 1971Founded Founded1

Calendar

Coming up

  1. Nov 5, 2026 · Before the openReports results for the quarter ending Sep/2026 A year earlier it reported $1.27 a share, on Nov 6, 2025.97

When it reported results

  1. Aug 6, 2026Reported quarterly or annual results87
  2. May 7, 2026Reported quarterly or annual results90
  3. Feb 5, 2026Reported quarterly or annual results94
  4. Nov 6, 2025Reported quarterly or annual results96
  5. Aug 7, 2025Reported quarterly or annual results98
  6. May 8, 2025Reported quarterly or annual results99
  7. Feb 6, 2025Reported quarterly or annual results100
  8. Nov 7, 2024Reported quarterly or annual results101

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

339 filings to the SEC since October 2021: 5 annual reports, 15 quarterly reports, 53 major events, 185 insider forms, 34 large holders, 47 other. The latest 20:

  1. Oct 8, 20268-K EDGAR
  2. Aug 18, 20268-K EDGAR
  3. Aug 12, 2026SCHEDULE 13G/A EDGAR
  4. Aug 6, 2026S-8 EDGAR
  5. Aug 6, 202610-Q EDGAR
  6. Aug 6, 20268-K EDGAR
  7. Jul 28, 20264 PRIMARY DOCUMENT EDGAR
  8. Jul 28, 20264 PRIMARY DOCUMENT EDGAR
  9. Jul 28, 20264 PRIMARY DOCUMENT EDGAR
  10. Jul 28, 20264 PRIMARY DOCUMENT EDGAR
  11. Jul 28, 20264 PRIMARY DOCUMENT EDGAR
  12. Jul 28, 20264 PRIMARY DOCUMENT EDGAR
  13. Jul 28, 20264 PRIMARY DOCUMENT EDGAR
  14. Jul 28, 20264 PRIMARY DOCUMENT EDGAR
  15. Jul 28, 20263 PRIMARY DOCUMENT EDGAR
  16. Jul 28, 20268-K EDGAR
  17. Jun 9, 2026ARS EDGAR
  18. Jun 9, 2026DEFA14A EDGAR
  19. Jun 9, 2026DEF 14A EDGAR
  20. Jun 8, 20264 PRIMARY DOCUMENT EDGAR

The 339 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

51 open-market trades by officers, directors and large owners since October 2021: 1 buys and 50 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Nov 10, 2025KROLL MARK WDirectorBuy1,400$70.56$98.8KForm 4
Jul 26, 2024Strong Stewart WPresident, Global HospitalSale4,312$91.15$393.0KForm 4
Jul 12, 2024Lingamneni AnilaEVP, Chief Technology OfficerSale79$90.00$7.1KForm 4
Jul 11, 2024Lingamneni AnilaEVP, Chief Technology OfficerSale2,136$90.00$192.2KForm 4
May 29, 2024Basil Michelle LEVP and General CounselSale12,990$88.08$1.1MForm 4
May 29, 2024Strong Stewart WPresident, Global HospitalSale8,857$87.53$775.3KForm 4
May 20, 2024Strong Stewart WPresident, Global HospitalSale686$95.11$65.2KForm 4
May 20, 2024Llorens JosepEVP, Global ManufacturingSale987$95.08$93.8KForm 4
May 20, 2024Basil Michelle LEVP and General CounselSale1,604$95.08$152.5KForm 4
May 17, 2024Llorens JosepEVP, Global ManufacturingSale822$94.82$77.9KForm 4
May 17, 2024Basil Michelle LEVP and General CounselSale1,073$95.00$101.9KForm 4
May 16, 2024Strong Stewart WPresident, Global HospitalSale733$96.04$70.4KForm 4
May 16, 2024Basil Michelle LEVP and General CounselSale985$96.14$94.7KForm 4
May 16, 2024Llorens JosepEVP, Global ManufacturingSale770$96.14$74.0KForm 4
May 6, 2024Lingamneni AnilaEVP, Chief Technology OfficerSale2,305$95.00$219.0KForm 4
Sep 12, 2023Strong Stewart WPresident, Global HospitalSale228$90.65$20.7KForm 4
Sep 11, 2023Lingamneni AnilaEVP, Chief Technology OfficerSale2,305$90.00$207.4KForm 4
Sep 5, 2023Dockendorff Charles JDirectorSale10,215$87.68$895.7KForm 4
Jul 18, 2023Llorens JosepEVP, Global ManufacturingSale4,928$90.00$443.5KForm 4
Jun 7, 2023Strong Stewart WPresident, Global HospitalSale2,538$88.04$223.4KForm 4

All 51 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2026Christopher A. SimonPresident and Chief Executive Officer62$1.1M$12.0M112
2026James C. D'AreccaExecutive Vice President, Chief Financial Officer$603.7K$3.6M112
2026Michelle L. BasilExecutive Vice President, General Counsel$558.8K$3.4M112
2026Frank W. ChanExecutive Vice President, Chief Operating Officer$518.3K$3.3M112
2026Roy GalvinExecutive Vice President, Chief Commercial Officer$550.2K$3.0M112
2025Christopher A. SimonPresident and Chief Executive Officer62$1.1M$10.7M112
2025James C. D'AreccaExecutive Vice President, Chief Financial Officer$575.6K$3.0M112
2025Michelle L. BasilExecutive Vice President, General Counsel$537.9K$2.8M112
2025Roy GalvinExecutive Vice President, Chief Commercial Officer$490.2K$2.2M112
2024Christopher A. SimonPresident and Chief Executive Officer62$1.1M$11.5M112
2024James C. D'AreccaExecutive Vice President, Chief Financial Officer$548.2K$3.1M112
2024Michelle L. BasilExecutive Vice President, General Counsel$517.2K$3.1M112

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
BlackRock, Inc.5,909,258$443.2M0.0%+289,279
Neuberger Berman Group LLC4,179,443$313.5M0.2%+618,525
Vanguard Portfolio Management LLC2,546,394$191.0M0.0%−12,922
Aqr Capital Management LLC2,266,489$165.0M0.1%−1,090,054
Ariel Investments, LLC2,060,966$154.6M1.5%New
Vanguard Capital Management LLC2,059,578$154.5M0.0%−30,811
State Street Corp1,818,186$136.4M0.0%+45,288
Dimensional Fund Advisors LP1,585,222$118.9M0.0%+259,165
Citadel Advisors LLC1,510,120$113.3M0.1%+1,251,967
Geode Capital Management, LLC1,287,240$96.6M0.0%+68,262
River Road Asset Management, LLC1,285,602$96.4M1.1%−42,387
Arrowstreet Capital, Limited Partnership1,155,351$86.7M0.0%−227,653
Goldman Sachs Group Inc1,046,019$78.5M0.0%+93,199
UBS Group AG983,378$73.8M0.0%+456,761
Fort Washington Investment Advisors Inc /oh/830,925$62.3M0.3%−10,092
Royal Bank Of Canada780,248$58.5M0.0%−77,717
Allspring Global Investments Holdings, LLC765,120$57.3M0.1%−125,104
Deutsche Bank Ag\631,663$47.4M0.0%+272,781
Northern Trust Corp631,542$47.4M0.0%+52,236
Charles Schwab Investment Management Inc591,423$44.4M0.0%+19,323
Boston Trust Walden Corp585,148$43.9M0.3%+83,263
Millennium Management LLC570,413$42.8M0.0%+560,629
Holocene Advisors, LP550,195$41.3M0.1%+545,673
Silvercrest Asset Management Group LLC493,796$37.0M0.2%+2,049
Morgan Stanley466,149$35.0M0.0%+172,710

13F reports cover disclosed long positions in U.S. stocks only.

Members of Congress who traded it

10 trades disclosed by members of Congress. “Vs S&P since” is the stock’s change since the trade minus the S&P 500’s.

DateMemberTradeAmountVs S&P sinceFiling
May 7, 2021Lois FrankelDemocratic, HouseSale$1,001 - $15,000−15.9%Report
May 6, 2021Lois FrankelDemocratic, HousePartial sale$1,001 - $15,000−13.2%Report
Jan 25, 2021Josh GottheimerDemocratic, HouseSale$1,001 - $15,000+102.3%Report
Oct 16, 2020Josh GottheimerDemocratic, HouseBuy$1,001 - $15,000−92.9%Report
Sep 15, 2020Josh GottheimerDemocratic, HousePartial sale$1,001 - $15,000+86.3%Report
Aug 14, 2020Lois FrankelDemocratic, HouseBuy$1,001 - $15,000−85.5%Report
Jun 1, 2020Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−142.2%Report
May 28, 2020Josh GottheimerDemocratic, HouseBuy$1,001 - $15,000−145.1%Report
May 19, 2020Gilbert Ray Cisneros, Jr.Democratic, HouseBuy$1,001 - $15,000−144.5%Report
May 15, 2020Josh GottheimerDemocratic, HouseBuy$1,001 - $15,000−148.7%Report

Members report amounts as ranges, not exact figures. Returns are price-only (no dividends).

SEC filer profile

How Haemonetics is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARHAEMONETICS CORP2
  • CIK0000313143
  • Employer ID (EIN)04-288227319
  • Filer statusLarge accelerated filer not an emerging growth company; not a smaller reporting company; not a shell company19
  • Incorporated inMassachusetts19
  • Fiscal year endsApril 32
  • Industry code (SIC)3841 Surgical & Medical Instruments & Apparatus2
  • SEC reviewing officeOffice of Industrial Applications and Services, Division of Corporation Finance2
  • Business address125 Summer Street, Boston, MA 021102
  • Phone78184871002
  • Shares outstanding45,497,051 as of Jul 31, 202617
  • Public float$2.2B as of Sep 27, 202519
  • AuditorErnst & Young LLP, Boston, Massachusetts PCAOB ID 42; it also attests to the company’s internal control over financial reporting19
  • On EDGAR sinceJun 7, 19962
  • Filings1,898 in all: 4 (1,112), 8-K (239), SC 13G/A (126), 10-Q (91), 3 (57), SC 13G (35), 10-K (31), DEF 14A (31)2
    All 35 form types

    144 (26), DEFA14A (15), SC 13D/A (15), UPLOAD (15), S-8 (13), SD (13), 4/A (12), CORRESP (12), 8-K/A (7), SCHEDULE 13G/A (7), 3/A (6), ARS (6), SC TO-T/A (6), PRE 14A (4), SCHEDULE 13G (4), 5 (2), CT ORDER (2), SC TO-C (2), 8-A12B (1), DEFS14A (1), EFFECT (1), NO ACT (1), POS AM (1), PRES14A (1), S-8 POS (1), SC 13D (1), SC TO-T (1)

  • Latest filingsAnnual report (10-K) May 20, 2026
    Quarterly report (10-Q) Aug 6, 2026
    Proxy statement (DEF 14A) Jun 9, 2026
    Latest 8-K (8-K) Oct 8, 2026

Securities registered for trading

ClassSymbolExchange
Common stock, $0.01 par value per shareHAENew York Stock Exchange

From the cover page of the 10-K filed May 20, 2026 (Section 12(b) of the Exchange Act).19

Risk factors and legal proceedings

The risks Haemonetics names in Item 1A of its 10-K filed May 20, 2026: 38 risks under these headings, as written.19

  • Risks Related to our Business and Industry
  • If our business strategy does not yield the expected results or we fail to implement the necessary changes to our operations, we could see material adverse effects on our business, financial condition or results of operations.
  • Material reductions in purchasing from or loss of a significant customer could adversely affect our business.
  • We face intense competition, and if we are unable to successfully expand our product lines through internal research and new product development or keep pace with rapid technological changes in the healthcare industry, our business may be materially and adversely affected.
  • Defects or quality issues associated with our products could adversely affect the results of operations.
  • If our business development activities are unsuccessful, we may not realize the intended benefits.
  • We are increasingly dependent on information technology systems and subject to privacy and security laws and a cyber-attack or other breach of these systems could have a material adverse effect on our business, financial condition or results of operations.
  • An inability to successfully manage the implementation of our new global enterprise resource planning system could adversely affect our operations and operating results.
  • We outsource certain aspects of our business to a single third-party vendor that subjects us to risks, including disruptions in business and increased costs.
  • Consolidation of healthcare providers and blood collectors, healthcare cost containment pressures, government payment and delivery system reforms and changes in private payer policies could decrease demand for our products, the prices which customers are willing to pay for those products and/or the number of procedures performed using our devices, which could have an adverse effect on our business, financial condition and results of operations.
  • An interruption in our ability to manufacture our products, obtain key components or raw materials, or the failure of a sole source supplier or sterilization service provider may adversely affect our business.
  • Changes in the cost, composition or availability of the plastics we purchase, or of other raw materials and components used in our products, could adversely affect our business, financial condition and results of operations.
The other 27 risks
  • We may not realize the benefits we expect from cost reduction initiatives.
  • Risks Related to Government Regulation
  • As a medical device manufacturer, we operate in a highly regulated industry, and non-compliance with applicable laws or regulations could adversely affect our financial condition and results of operations.
  • If we or our suppliers fail to comply with laws and regulations governing the manufacture and production of our products, our products could be subject to restrictions or withdrawal from the market.
  • As a medical device manufacturer, we are subject to safety reporting requirements.
  • Our relationships with customers and third-party payers are subject to applicable anti-kickback, fraud and abuse, transparency and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, exclusion, contractual damages, reputational harm and diminished profits and future earnings.
  • Changes in tax laws or exposure to additional income tax liabilities could have a material impact on our financial condition, results of operations and/or liquidity.
  • Risks Related to our Financial Obligations and Indebtedness
  • We have a significant amount of debt that may decrease our business flexibility, access to capital, and/or increase our borrowing costs, and we may still incur additional debt in the future, which may adversely affect our operations and financial results.
  • The conditional conversion feature of the 2029 Notes, if triggered, may adversely affect our financial condition and operating results.
  • The Capped Call Transactions may affect the value of the 2029 Notes and our common stock.
  • We are subject to counterparty risk with respect to the Capped Call Transactions.
  • Provisions in the Indentures could delay or prevent an otherwise beneficial takeover of us.
  • Conversion of the 2029 Notes may dilute the ownership interest of existing stockholders.
  • Risks Related to Operating Internationally
  • As a substantial amount of our revenue comes from outside the U.S., we are subject to geopolitical events, economic volatility, violations of anti-corruption laws, export and import restrictions and tariffs, decisions by local regulatory authorities and the laws and medical practices in foreign jurisdictions.
  • We sell our products in certain emerging economies which exposes us to less mature regulatory systems, more volatile markets for our products and greater credit risks. A loss of funding for our products or changes to the regulatory regime could lead to lost revenue or account receivables.
  • In many of the international markets in which we do business, including certain parts of Europe, South America, the Middle East and Asia, our employees, agents or distributors offer to sell our products in response to public tenders issued by various governmental agencies.
  • We are exposed to fluctuations in currency exchange rates, which could adversely affect our cash flows and results of operations.
  • Our effective tax rate may fluctuate and we may incur obligations in tax jurisdictions in excess of amounts that have been accrued.
  • Risks Related to Intellectual Property and Litigation
  • There is a risk that our intellectual property may be subject to misappropriation in some countries.
  • Pending and future intellectual property litigation could be costly and disruptive to us.
  • Our products may be determined to infringe on another party’s patent, which could lead to financial losses or adversely affect our ability to market our products.
  • We operate in an industry susceptible to significant product liability claims. Pending and future product liability claims and other litigation may adversely affect our financial condition and results of operations or liquidity, and they also have the potential to damage our reputation, impair our ability to market our products and impact our ability to maintain applicable insurance coverage on reasonable terms or at all.
  • General Risk Factors
  • Our success depends on our ability to attract and retain key personnel needed to successfully operate the business and to plan for future executive transitions.
  • Our share price has been volatile and may fluctuate, and accordingly, the value of an investment in our common stock may also fluctuate.
  • Share repurchase programs, including under our existing share repurchase authorization, could affect the price of our common stock and increase volatility and may be suspended or terminated at any time, which may result in a decrease in the trading price of our common stock.
  • Our business could be negatively impacted by corporate responsibility matters.
  • Climate change, or legal, regulatory or market measures to address climate change, could adversely affect our business, results of operations and financial condition.
  • Actual or threatened public health crises could harm our business.

Legal proceedings

Information with respect to this Item may be found in Note 15, Commitments & Contingencies, within the consolidated financial statements in Item 8 of this Annual Report on Form 10-K, which is incorporated herein by reference.

The opening of Item 3, Legal Proceedings.19

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52
  53. 53
  54. 54
  55. 55
  56. 56
  57. 57
  58. 58
  59. 59
  60. 60
  61. 61
  62. 62
  63. 63
  64. 64
  65. 65
  66. 66
  67. 67
  68. 68
  69. 69
  70. 70
  71. 71
  72. 72
  73. 73
  74. 74
  75. 75
  76. 76
  77. 77
  78. 78
  79. 79
  80. 80
  81. 81
  82. 82
  83. 83
  84. 84
  85. 85
  86. 86
  87. 87
  88. 88
  89. 89
  90. 90
  91. 91
  92. 92
  93. 93
  94. 94
  95. 95
    SEC EDGAROther events
  96. 96
  97. 97
  98. 98
  99. 99
  100. 100
  101. 101
  102. 102
  103. 103
  104. 104
  105. 105
  106. 106
  107. 107
  108. 108
  109. 109
  110. 110
  111. 111
  112. 112